Last reviewed · How we verify

NCT04810832: EXPRESON-IN

EXPRESON-IN : Intracerebral Recordings of P3a Responses to Expressive Own-names

Status unknown NA Last updated 9 July 2021
What this trial tests

NA trial testing Evoked related potentials in Intractable Epilepsy in 20 participants. Status unknown.

Timeline
9 September 2020
Primary endpoint
9 September 2022
9 September 2023

Quick facts

Lead sponsorCentre Hospitalier St Anne
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposebasic science
Enrollment20
Start date9 September 2020
Primary completion9 September 2022
Estimated completion9 September 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier St Anne

Who can join

18 and older, any sex, with Intractable Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neurophysiologic evaluation of disorders of consciousness (DOC) patients in intensive care unit include late auditory evoked potentials. It allows the physicians to record cerebral responses of patients to auditory stimuli and in particularly to their own name (as the P3a response). Numerous studies try to improve the relevance of the auditory stimuli used in this paradigm and notably using more expressive stimuli. Here the investigators investigate the intracerebral correlates of the P3a responses recorded on the scalp with neutral and more expressive stimuli.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intractable Epilepsy

Currently open trials in the same condition.

Other Centre Hospitalier St Anne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04810832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing